Proven Target (Antagonist)ADG104
Product 5 SAFEbody
ADG-106 is the only monoclonal antibody against this target that has demonstrated potent single agent efficacy in multiple tumor models with intact immune system and work in synergy with other therapeutics, while maintaining an excellent safety profile at extremely high dose.
ADG106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137 is currently in clinical trials conducted both in China and in the US, investigating its safety in advanced and/or refractory solid tumors and lymphomas.
- ADG106Advanced or Metastatic Solid Tumors and/or Non-Hodgkin LymphomaA Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (Protocol number: ADG106-1001)CLINICAL TRIALS
- Therapeutic AreaAdvanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
- ProjectA Study of CD137 Agonist ADG106 Administered Intravenously in Patients with Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (Protocol number: ADG106-1001)CLINICAL TRIALS
The Dynamic Precision Library Platform (DPL) represents a fundamental advancement in antibody discovery. The proprietary DPL libraries are designed with precision and constructed with very high fidelity. They vastly expand the druggable universe and create highly focused diversity that finely differentiates between epitopic diversity, to reach unmatched binding precision and specificity. The resulting functional antibodies consistently demonstrate uniquely favorable characteristics with differentiated product profiles.
Adagene’s proprietary SAFEbodyTM platform is a precision antibody masking technology that is designed to enhance the safety profile of therapeutic antibodies. The SAFEbodyTM is activated specifically in disease tissues in order to lower its systemic toxicity and to broaden its therapeutic windows. By using SAFEbodyTM platform, Adagene and its partners can create a robust pipeline of products with an improved safety profile, allowing for the development of new therapies against important cancer targets which previously failed conventional antibody based therapeutics due to “on-target” but “off-tumor toxicity”.